These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23598371)

  • 21. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
    Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
    Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003).
    Sandset EC; Murray G; Boysen G; Jatuzis D; Kõrv J; Lüders S; Richter PS; Roine RO; Terént A; Thijs V; Berge E;
    Int J Stroke; 2010 Oct; 5(5):423-7. PubMed ID: 20854630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
    Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
    Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].
    Shao JQ; Iwashita N; Du H; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):306-10. PubMed ID: 17637271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study.
    Matharu MS; Levy MJ; Meeran K; Goadsby PJ
    Ann Neurol; 2004 Oct; 56(4):488-94. PubMed ID: 15455406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study.
    Ambrosini A; Vandenheede M; Rossi P; Aloj F; Sauli E; Pierelli F; Schoenen J
    Pain; 2005 Nov; 118(1-2):92-6. PubMed ID: 16202532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
    Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
    J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study.
    Stovner LJ; Linde M; Gravdahl GB; Tronvik E; Aamodt AH; Sand T; Hagen K
    Cephalalgia; 2014 Jun; 34(7):523-32. PubMed ID: 24335848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
    Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
    Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
    Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
    Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.